Osimertinib as Adjuvant Therapy in EGFR-Mutant Lung Cancer Osimertinib as Adjuvant Therapy in EGFR-Mutant Lung Cancer

Dr Mark Kris discusses how recent data presented at ESMO continue to support osimertinib as an important drug in the adjuvant setting for patients with completely resected EGFR-mutant lung cancer.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news